Clozel’s Actelion R&D spinout gets a name; GSK’s new CEO won’t make as much as her predecessor

→ Jean-Paul Clozel has a name for his biotech spinout. Once J&J’s $30 billion deal to acquire Actelion goes through, the R&D side of the business will launch under the name Idorsia. When the deal was originally announced, Clozel had pencilled in NewCo for his next venture.

→ Aurinia $AUPH took advantage of a rising share price to round up $150 million in a new offering. But the stock took a beating Tuesday after the biotech decided to offer the shares at a deep discount.

→ New GSK CEO Emma Walmsley won’t be paid as well as her predecessor, Andrew Witty. The pharma giant overall is cutting the pay packet by 25% for Walmsley, who is stepping up to her first job as CEO. The company performed a review of its pay practices, aware of some criticism it’s been getting as generic Advair makes its way to the market.

The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.Email:

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.Email:

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 19,000+ biopharma executives who read Endpoints News every day.